Clinical trial
A Phase I/IIa Theranostic Study of 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer
NCT04868604 is registered in ClinicalTrials.gov with Clarity Pharmaceuticals Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I/IIa Theranostic Study of 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer
- Lead sponsor
- Clarity Pharmaceuticals Ltd
- Phase
- Phase 1/2
- Overall status
- Recruiting
- Start date
- August 11, 2021
- Completion date
- September 30, 2026
- Enrollment
- 54 (estimated)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.